LIWANLI Innovation Co., Ltd. (3054.TW)
TWD 23.5
(1.29%)
TWD 23.5
(1.29%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | - TWD | 66.83% |
| 2022 | -119.94 Million TWD | -307.67% |
| 2021 | 57.75 Million TWD | 452.06% |
| 2020 | -16.4 Million TWD | -221.11% |
| 2019 | 13.54 Million TWD | 124.12% |
| 2018 | -56.15 Million TWD | 56.26% |
| 2017 | -128.39 Million TWD | -485.72% |
| 2016 | -21.92 Million TWD | 79.28% |
| 2015 | -105.79 Million TWD | -397.7% |
| 2014 | -21.25 Million TWD | -109.37% |
| 2013 | 226.77 Million TWD | 417.27% |
| 2012 | -71.47 Million TWD | -543.07% |
| 2011 | -11.11 Million TWD | 70.55% |
| 2010 | -37.74 Million TWD | -154.39% |
| 2009 | 69.39 Million TWD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -11.19 Million TWD | -3.44% |
| 2024 Q2 | -10.82 Million TWD | -12.89% |
| 2024 Q1 | -9.58 Million TWD | 17.04% |
| 2023 Q3 | -14.42 Million TWD | -63.31% |
| 2023 Q2 | -8.83 Million TWD | -155.74% |
| 2023 Q1 | 15.85 Million TWD | 229.86% |
| 2023 FY | -39.78 Million TWD | 66.83% |
| 2023 Q4 | -11.55 Million TWD | 19.91% |
| 2022 Q2 | -77.93 Million TWD | -1805.89% |
| 2022 FY | -119.94 Million TWD | -307.67% |
| 2022 Q4 | -12.2 Million TWD | -4.43% |
| 2022 Q1 | -4.08 Million TWD | -141.31% |
| 2022 Q3 | -11.68 Million TWD | 85.0% |
| 2021 FY | 57.75 Million TWD | 452.06% |
| 2021 Q1 | -19.32 Million TWD | 46.51% |
| 2021 Q2 | -21.45 Million TWD | -11.01% |
| 2021 Q3 | 1.66 Million TWD | 107.77% |
| 2021 Q4 | 9.89 Million TWD | 493.76% |
| 2020 Q2 | -26.52 Million TWD | -30.94% |
| 2020 Q1 | -20.25 Million TWD | -22.74% |
| 2020 FY | -16.4 Million TWD | -221.11% |
| 2020 Q4 | -36.12 Million TWD | -45.85% |
| 2020 Q3 | -24.77 Million TWD | 6.62% |
| 2019 FY | 13.54 Million TWD | 124.12% |
| 2019 Q2 | -14.51 Million TWD | 42.53% |
| 2019 Q3 | -20.07 Million TWD | -38.29% |
| 2019 Q1 | -25.25 Million TWD | -174.34% |
| 2019 Q4 | -16.5 Million TWD | 17.76% |
| 2018 Q3 | -12.1 Million TWD | -4.82% |
| 2018 Q2 | -11.55 Million TWD | 50.41% |
| 2018 Q4 | -9.2 Million TWD | 23.98% |
| 2018 FY | -56.15 Million TWD | 56.26% |
| 2018 Q1 | -23.29 Million TWD | 60.85% |
| 2017 Q4 | -59.5 Million TWD | -66.38% |
| 2017 Q1 | -8.58 Million TWD | -224.22% |
| 2017 Q2 | -24.54 Million TWD | -186.09% |
| 2017 Q3 | -35.76 Million TWD | -45.68% |
| 2017 FY | -128.39 Million TWD | -485.72% |
| 2016 Q4 | 6.9 Million TWD | 147.55% |
| 2016 Q1 | -6.25 Million TWD | 82.98% |
| 2016 FY | -21.92 Million TWD | 79.28% |
| 2016 Q2 | -8.04 Million TWD | -28.71% |
| 2016 Q3 | -14.52 Million TWD | -80.52% |
| 2015 Q1 | -18.14 Million TWD | 41.86% |
| 2015 FY | -105.79 Million TWD | -397.7% |
| 2015 Q4 | -36.74 Million TWD | -15.42% |
| 2015 Q3 | -31.83 Million TWD | -66.87% |
| 2015 Q2 | -19.07 Million TWD | -5.14% |
| 2014 Q4 | -31.2 Million TWD | -74.8% |
| 2014 FY | -21.25 Million TWD | -109.37% |
| 2014 Q1 | 17.68 Million TWD | -52.46% |
| 2014 Q2 | 10.11 Million TWD | -42.79% |
| 2014 Q3 | -17.85 Million TWD | -276.44% |
| 2013 Q4 | 37.2 Million TWD | 221.64% |
| 2013 FY | 226.77 Million TWD | 417.27% |
| 2013 Q1 | 91.13 Million TWD | 697.33% |
| 2013 Q2 | 86.86 Million TWD | -4.68% |
| 2013 Q3 | 11.56 Million TWD | -86.68% |
| 2012 Q3 | -56.02 Million TWD | -5791.17% |
| 2012 Q1 | 812 Thousand TWD | -88.95% |
| 2012 FY | -71.47 Million TWD | -543.07% |
| 2012 Q4 | -15.25 Million TWD | 72.77% |
| 2012 Q2 | -951 Thousand TWD | -217.12% |
| 2011 Q2 | -36.15 Million TWD | -463.35% |
| 2011 Q3 | 7.74 Million TWD | 121.42% |
| 2011 Q4 | 7.34 Million TWD | -5.15% |
| 2011 FY | -11.11 Million TWD | 70.55% |
| 2011 Q1 | 9.95 Million TWD | 383.99% |
| 2010 Q2 | -19.64 Million TWD | -266.05% |
| 2010 FY | -37.74 Million TWD | -154.39% |
| 2010 Q3 | -26.42 Million TWD | -34.54% |
| 2010 Q1 | 11.82 Million TWD | 0.0% |
| 2010 Q4 | -3.5 Million TWD | 86.74% |
| 2009 FY | 69.39 Million TWD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Grape King Bio Ltd | 2.49 Billion TWD | 100.0% |
| Standard Chem & Pharm CO., LTD. | 1.25 Billion TWD | 100.0% |
| Maywufa Company Ltd. | 211.01 Million TWD | 100.0% |
| ScinoPharm Taiwan, Ltd. | 314.49 Million TWD | 100.0% |
| Lotus Pharmaceutical Co., Ltd. | 4.9 Billion TWD | 100.0% |
| YungShin Global Holding Corporation | 929.61 Million TWD | 100.0% |
| PhytoHealth Corporation | -121.67 Million TWD | 100.0% |
| SCI Pharmtech, Inc. | 160.3 Million TWD | 100.0% |
| Formosa Laboratories, Inc. | 674.97 Million TWD | 100.0% |
| PharmaEssentia Corporation | - TWD | NaN% |
| Bora Pharmaceuticals Co., LTD. | 5.24 Billion TWD | 100.0% |